| Description | ALDH18A1 Human Pre-designed siRNA Set A contains three designed siRNAs for ALDH18A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components ALDH18A1 siRNA-1: 5 nmol (HPLC) ALDH18A1 siRNA-2: 5 nmol (HPLC) ALDH18A1 siRNA-3: 5 nmol (HPLC) siRNA ALDH18A1 Human Pre-designed siRNA Set A contains three designed siRNAs for ALDH18A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components ALDH18A1 siRNA-1: 5 nmol (HPLC) ALDH18A1 siRNA-2: 5 nmol (HPLC) ALDH18A1 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Biochemical Test:SDS-PAGE (purity > 80%); Western blot with patient sample.Calculated Isoelectric Point:pH 6.10 | Dezamizumab (anti-Serum Amyloid P) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab (anti-Serum Amyloid P) triggers immunotherapeutic clearance of amyloid. Dezamizumab (anti-Serum Amyloid P) can be used Dezamizumab (anti-Serum Amyloid P) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab (anti-Serum Amyloid P) triggers immunotherapeutic clearance of amyloid. Dezamizumab (anti-Serum Amyloid P) can be used in research of Amyloid light-chain (AL) amyloidosis... Read More | The Leuconostoc GPDH exhibits dual coenzyme specificity, namely NAD and NADP (Olive and Levy, Biochem., 6, 730 730, 1967). When assayed under conditions that are optimal for the particular coenzyme, the ratio of observed catalytic activity is NAD/NADP = 1.8 | Inquire |